GLP-1 Drugs Show Heart Benefits But Stopping Them Raises Risk
New studies indicate GLP-1 medications reduce cardiovascular risks while active, but discontinuation significantly increases the likelihood of heart attacks and strokes.
Headline and summary written by an AI model from the linked articles; not reviewed by a person. How this was made
The odds
Each tick is a source publishing on this story
Price data
| Time | Chance of yes |
|---|---|
| now | 3% |
| 20 Nov, 00:03 UTC | 3% |
The story so far
2 publishers have covered this in 2 articles since 20 Nov 2026. South China Morning Post published first, on 20 November at 23:15 UTC; Inc. followed 20h 11m later. The most recent article, from Inc., appeared on 21 November at 19:25 UTC.
Outlets reporting it: South China Morning Post, Inc..
One prediction market prices this story:
- Before Jan 1, 2027 — the market puts it at 3%, closing 1 Jan 2027. The market resolves to Yes if the Centers for Medicare and Medicaid Services (CMS) officially announces that GLP-1 drugs are added to Part D coverage for obesity before January 1, 2027. Otherwise, it resolves to No. Readers often mistake general enrollment numbers or news reports for the official CMS announcement required for resolution.
Odds are the market's probability that the outcome happens, updated every few minutes. They are information about what traders expect, not a forecast we make and not investment advice.
Sources
Every article we clustered into this story. Headlines link to the publisher.
Related prediction markets
Linked by software because they are about the same subject. Most ask a different question from the one this story reports, so read each market's own question. How often the link is right
- Kalshi Before Jan 1, 2027 3%
Does the market have this right?
Wrong market?
Have your say
Your call. How does this end?
Free, no money involved. Calls are scored against the market's price when you make them, so backing an underdog that wins scores most. Leaderboard · Your calls
Alert me when the odds move
In this story
- Mayo Clinic
- The Lancet Regional Health Europe